ERBB2 and breast cancer: As the first humanized mAb against HER2, trastuzumab (Herceptin) is approved by the Food and Drug Administration (FDA) for HER2-positive BC, and it has been widely labeled by radionuclide, including 111In, 124I, 64Cu, and 89Zr [22,23,24,25].